Headlines about Vanda Pharmaceuticals (NASDAQ:VNDA) have been trending somewhat positive recently, according to Accern. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.3287948630322 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several equities research analysts have weighed in on VNDA shares. BidaskClub upgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 2nd. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “buy” rating and set a $17.00 target price for the company in a research note on Friday, April 20th. Citigroup initiated coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 23rd. They set a “buy” rating and a $26.00 price objective for the company. Oppenheimer reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, March 22nd. Finally, ValuEngine upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 12th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $22.14.
Shares of NASDAQ:VNDA traded down $0.05 on Tuesday, hitting $19.15. 1,170 shares of the company were exchanged, compared to its average volume of 456,643. Vanda Pharmaceuticals has a 1-year low of $11.90 and a 1-year high of $20.40. The company has a market capitalization of $995.31 million, a P/E ratio of -54.57 and a beta of 0.96.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, May 2nd. The biopharmaceutical company reported $0.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.23. Vanda Pharmaceuticals had a negative net margin of 2.84% and a negative return on equity of 3.06%. The business had revenue of $43.59 million during the quarter, compared to the consensus estimate of $43.30 million. During the same period in the previous year, the firm posted ($0.11) earnings per share. The business’s revenue for the quarter was up 16.6% compared to the same quarter last year. research analysts forecast that Vanda Pharmaceuticals will post -0.05 earnings per share for the current fiscal year.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.